PHF20

更新于：2025-05-07

基本信息

别名

C20orf104、dJ1121G12.1、GLEA2

+ [10]

简介

Methyllysine-binding protein, component of the MOF histone acetyltransferase protein complex. Not required for maintaining the global histone H4 'Lys-16' acetylation (H4K16ac) levels or locus specific histone acetylation, but instead works downstream in transcriptional regulation of MOF target genes (By similarity). As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues. Contributes to methyllysine-dependent p53/TP53 stabilization and up-regulation after DNA damage.

关联

100 项与 PHF20 相关的临床结果

登录后查看更多信息

100 项与 PHF20 相关的转化医学

登录后查看更多信息

0 项与 PHF20 相关的专利（医药）

登录后查看更多信息

123

项与 PHF20 相关的文献（医药）

2025-12-01·Functional & Integrative Genomics

Epigenetic modification mediated by PHF20/METTL14/HOXA13 signaling axis modulates osteogenic differentiation of mesenchymal stem cells

Article

作者: Chen, Ting ; Feng, Weijia

This study investigates the mechanism of PHF20 in osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). BMSCs from Balb/c mouse were cultured and identified through osteogenesis, adipogenesis, and flow cytometry. After osteogenic induction, the levels of OPN and OCN in BMSCs were detected by RT-qPCR. Alizarin red staining and alkaline phosphatase (ALP) staining were used to evaluate the osteogenic differentiation ability of BMSCs. PHF20, METTL14, and HOXA13 expressions were detected by RT-qPCR and Western blot. After quantitative analysis of m6A level, RNA immunoprecipitation (RIP) was performed to measure the enrichment of IGF2BP3 or m6A on HOXA13 mRNA. HOXA13 mRNA stability was assessed after actinomycin D treatment. PHF20, METT14, and HOXA13 expressions gradually increased during osteogenic differentiation of BMSCs. Suppression of PHF20 expression repressed the osteogenic differentiation of BMSCs, mainly resulted in a decrease in OPN and OCN levels, reduced mineralization, and weakened ALP activity. Mechanistically, PHF20 elevated METTL14 expression by enhancing the enrichment of H3K4me3 on its promoter, and METTL14 strengthened HOXA13 m6A methylation to maintain HOXA13 mRNA stability through IGF2BP3. In conclusion, PHF20 elevates METTL14 expression by enhancing H3K4me3 enrichment on its promoter and enhances HOXA13 mRNA stability via IGF2BP3-mediated m6A modification, thus facilitating HOXA13 expression and eventually inducing osteogenic differentiation of BMSCs.

2025-03-28·Reproduction

Meiotic arrest, resumption and TZP retraction in bovine COCs undergoing pre-IVM: lessons from a refined GV stage classification

Article

作者: da Silveira, Juliano Coelho ; Perecin, Felipe ; Saraiva, Helena Fabiana Reis de Almeida ; Sangalli, Juliano Rodrigues ; Alves, Luana ; Meirelles, Flávio Vieira

In briefOocytes with subtle differences in chromatin configuration and nuclear lamina characteristics, detectable by a refined germinal vesicle (GV) classification system here described, respond differently to meiotic maturation systems leading to different in vitro maturation (IVM) outcomes.AbstractThe nuclear, cytoplasmic and molecular maturation of the mammalian oocyte is a finely orchestrated sequence of events that relies on proper cumulus–oocyte communication. Bovine oocytes enter the IVM systems at the GV stage exhibiting four different chromatin configurations (GV0–GV3). Herein, we associate the oocyte chromatin and nuclear lamina configurations to propose a refined GV classification (GV0, GV1.1–GV1.3, GV2.1–GV2.3 and GV3.1–GV3.3). This refined GV classification system was correlated with oocyte meiosis resumption and transzonal projections (TZPs) density of cumulus–oocyte complexes (COCs) submitted to three IVM systems (control IVM and a modified IVM preceded or not by a pre-IVM step). Pre-IVM resulted in lower polar body extrusion rates at 19 h IVM, albeit ∼24% of the oocytes extruded their first polar body at 9 h IVM. Pre-IVM sustained 80% of oocytes meiotically arrested but altered GV distribution, reducing GV2 and increasing GV1.3 and GV3.3 categories. Pre-IVM reduced TZP densities predominantly in pre-matured GV3 and GVBD COCs. At 9 h of IVM, both groups matured in modified IVM showed lower TZP densities compared to immature and IVM control. Gene expression supports the TZP density differences, with ERK2 and PRKACA upregulation in pre-matured cumulus and in modified IVM groups at 9 h of IVM. GDF9 and BMP15 levels were similar between treated and control groups at all time points. Our findings indicate that despite the IVM system, the initial oocyte GV stage influences pre-IVM and IVM outcomes. The refined GV classification system is a useful tool to oocyte biologists.

2025-01-01·Toxicological Research

Enhancement of renal fibrosis in PHF20 transgenic mice

Article

作者: Lee, Soohyeon ; Kim, In Soo ; Park, Jongsun ; Jung, Woohyeong ; Gwon, Suhwan ; Lee, Beomwoo ; Kwon, So Hee ; Kim, Seon-Hwan ; Nguyen, Huonggiang ; Juang, Uijin ; Huang, Qingzhi

Plant homeodomain finger protein 20 (PHF20) plays a crucial role in various biological processes, but its involvement in renal fibrosis remains unclear. This study investigated the role of PHF20 in renal fibrosis using a unilateral ureteral obstruction (UUO) mouse model, a widely accepted model for chronic kidney disease. PHF20 transgenic (PHF20-TG) and wild-type (WT) mice were utilized to explore how PHF20 influences renal inflammation and fibrosis. After UUO surgery, serum analysis revealed elevated creatinine levels and increased inflammatory markers, indicating worsened renal function in PHF20-TG mice. Histological analyses, including H&E, PAS, and Sirius Red staining, confirmed significant tissue damage and fibrosis in the PHF20-TG group. Molecular investigations demonstrated enhanced activation of the TGF-β/SMAD2/3 and NF-κB signaling pathways, both of which are crucial in the progression of renal fibrosis. Our findings suggest that PHF20 overexpression accelerates early-stage renal fibrosis by amplifying inflammatory responses and promoting collagen deposition. This indicates that PHF20 expression could serve as an early marker for renal fibrosis progression.

项与 PHF20 相关的新闻（医药）

2020-08-31

·礼来中国

Tirzepatide心血管结局试验(SURPASS-CVOT)达成首个中国患者给药治疗

今日，礼来中国宣布，评估GIP和GLP-1双受体激动剂tirzepatide(TZP, LY3298176)的全球III期心血管结局试验SURPASS-CVOT已对首例中国患者进行了随机并给药治疗。这是一项头对头试验，将评估TZP相较于GLP-1受体激动剂度拉糖肽1.5mg在心血管结局中的非劣效性和优效性。 SURPASS-CVOT(NCT04255433)包括来自全球30个国家12,500例合并心脑血管疾病的2型糖尿病患者，中国参与了该研究。主要终点是观察首次出现MACE-3【即心血管(CV)死亡、心肌梗死、卒中的复合终点】的时间。关键次要终点包括全因死亡发生时间和主要终点中每个组成部分的发生时间。该试验预计将需要4年时间完成。该研究的中国共同主要研究者，北京大学人民医院内分泌科主任纪立农教授和首都医科大学附属北京安贞医院心内科中心主任马长生教授表示:“礼来TZP的II期临床结果 1 令人振奋，TZP或可成为糖尿病领域新药研发的新标杆。本次的CVOT设计颇为大胆，将TZP与度拉糖肽进行比较，后者已经被证明有明确的心血管保护作用。这是全球首次采用已获得心血管获益证据的降糖药物作为活性对照药物的研究。SURPASS-CVOT研究将为临床医生提供重要的证据，即：在同时患有2型糖尿病和心脑血管疾病的患者中，TZP在心血管结局方面是否具有超越当今具有卓越效果的GLP-1受体激动剂的潜力。中国20多家医院将参与该研究，并且心内科与内分泌科同时入选患者。这是一种新的合作模式，也必将为糖尿病合并心血管疾病共同管理带去重大变革。期待能在中国早日完成该临床试验，将药物与管理模式的突破转化为临床实践，帮助更多中国患者获益。” 礼来公司中国高级副总裁，药物发展与医学事务中心负责人王莉博士表示:“中国糖尿病和心血管疾病患者较多，存在诸多未满足的临床需求，礼来中国糖尿病研发布局和策略与中国患者的需求密切相关。从第一个胰岛素上市至今，礼来中国始终深耕在糖尿病领域的研发，而TZP CVOT是礼来中国首次在糖尿病领域投入的长期结局研究，并首次真正实现糖尿病治疗领域全球同步研发。该研究直接与已证实心血管获益的礼来已上市产品度拉糖肽进行头对头的研究设计，充分展现了礼来公司对TZP新药的信心，也希望该试验早日完成，期待SURPASS-CVOT的结果能给中国患者带来更多的获益。” 关于礼来制药礼来制药是一家全球领先的医药公司，致力于通过创新改善人类健康水平。礼来制药诞生于一个多世纪之前，公司创始人致力于生产高质量的药品以满足切实的医疗需求。今天，我们仍然执着于这一使命，并基于此开展工作。在全球范围内，我们的员工始终努力研发能为人类生活带来改变的药物，并将其提供给那些切实所需的患者。不仅如此，我们还致力于改善公众对于疾病的理解、并更好地开展疾病管理，同时通过投身于慈善事业和志愿者活动回馈社会。如果需要了解更多关于礼来制药的信息，请登录：www.lilly.com。参考资料： 1. Juan Pablo Frias, el at., 2018. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. www.thelancet.com PP-LD-CN-1665

分析

对领域进行一次全面的分析。

或

查看完整样例数据

生物医药百科问答

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。